Scopus BioPharma Inc (SCPS)

Etorro trading 970x250
Scopus BioPharma Inc (SCPS) Logo

About Scopus BioPharma Inc

Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York. Address: 420 Lexington Avenue, New York, NY, United States, 10170

Scopus BioPharma Inc News and around…

Latest news about Scopus BioPharma Inc (SCPS) common stock and company :

Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market
22 Nov, 2021 Yahoo! Finance

NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it has entered into securities purchase agreements with certain institutional investors in connection with a private placement priced at-the-market under Nasdaq rules of 3,000,000 shares of common stock, series A additional investment options (the “Series A

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
08 Nov, 2021 Yahoo! Finance

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that, on November 5, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 11:30 a.m., Eastern time, on Monday, December 20, 2021, without any business being conducted. The adjourned meeting will be held by means of remote communication and can be accessed via the following URL: http://www.cesonlineservices.com/scps21_vm. The adjournment date is pursuant to an unders

We Did The Math IWC Can Go To $208
04 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $207.52 per unit.

12 Health Care Stocks Moving In Monday's After-Market Session
25 Oct, 2021 FinancialContent

Gainers Medpace Hldgs (NASDAQ:MEDP) shares moved upwards by 10.73% to $208.6 during Monday's after-market session. The market value ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
14 Oct, 2021 FinancialContent

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 34.63% to $12.71 during Thursday's pre-market session. ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Scopus BioPharma to Present at the LD Micro Main Event
05 Oct, 2021 Yahoo! Finance

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it wi

18 Stocks Moving in Monday's Pre-Market Session
04 Oct, 2021 FinancialContent

Gainers CohBar, Inc. (NASDAQ: CWBR) rose 22.8% to $1.13 in pre-market trading after dropping over 4% on Friday. Farmmi, Inc.. ...

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
01 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation. In the past several weeks, the shares of Scopus BioPharma have come under attack by abusive short sellers. During this period, the short volume ratio has reached nearly 70% and over 25% of the company’s market capitalization has been wiped out. The downward pr

Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference
01 Oct, 2021 Yahoo! Finance

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it wi

Implied IWC Analyst Target Price: $204
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $204.00 per unit.

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
29 Sep, 2021 FinancialContent
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
28 Sep, 2021 Yahoo! Finance

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS MeetingNEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that Duet Therapeutics, a wholly-owned subsidiary of Scopus, will release scientific data during the 17th Annual Mee

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
28 Sep, 2021 FinancialContent

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
28 Sep, 2021 FinancialContent
Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference
23 Sep, 2021 FinancialContent

Scopus to present on launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
22 Sep, 2021 FinancialContent
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
21 Sep, 2021 FinancialContent
48 Biggest Movers From Yesterday
21 Sep, 2021 FinancialContent

Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 ...

12 Health Care Stocks Moving In Monday's Intraday Session
20 Sep, 2021 FinancialContent

Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. ...

Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
20 Sep, 2021 Yahoo! Finance

Dr. Morris C. Laster today announced that he has filed preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with the 2021 Annual Meeting of Stockholders ("Annual Meeting") of Scopus BioPharma Inc. (Nasdaq: SCPS) ("Scopus" or the "Company") scheduled for October 8, 2021. Dr. Laster, together with the other participants in his solicitation, own approximately 33.2% of the outstanding shares of the Company's common stock. Dr. Laster has nominated two highly-q

12 Health Care Stocks Moving In Friday's After-Market Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) shares moved upwards by 8.27% to $5.76 during Friday's after-market session. This ...

Could The Scopus BioPharma Inc. (NASDAQ:SCPS) Ownership Structure Tell Us Something Useful?
15 Sep, 2021 Yahoo! Finance

Every investor in Scopus BioPharma Inc. ( NASDAQ:SCPS ) should be aware of the most powerful shareholder groups...

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board
14 Sep, 2021 FinancialContent
Scopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 FinancialContent

Scopus to Present on Launch of Duet Therapeutics, its Wholly-Owned Subsidiary Focused on Immuno-Oncology

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor
07 Sep, 2021 FinancialContent
53 Biggest Movers From Friday
07 Sep, 2021 FinancialContent

Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock ...

12 Health Care Stocks Moving In Friday's Intraday Session
03 Sep, 2021 FinancialContent

Gainers Cellect Biotechnology (NASDAQ:APOP) stock increased by 29.9% to $7.14 during Friday's regular session. Trading volume for ...

Scopus BioPharma Inc (SCPS) is a NASDAQ Common Stock listed in , ,

970x250